Caputo, Roberta
Cazzaniga, Marina Elena
Sbrana, Andrea
Torrisi, Rosalba
Paris, Ida
Giordano, Monica
Montesarchio, Vincenzo
Guarneri, Valentina
Amaducci, Laura
Bilancia, Domenico
Cilenti, Giuseppina
Fabi, Alessandra
Collovà, Elena
Schirone, Alessio
Bonizzoni, Erminio
Celio, Luigi
De Placido, Sabino
De Laurentiis, Michelino
Article History
Received: 12 July 2019
Accepted: 3 March 2020
First Online: 19 March 2020
Ethics approval and consent to participate
: This study was approved by the Institutional Review Board of the National Cancer Institute “Fondazione Pascale”, Naples (IRB number 70/15), and this trial is registered with ExternalRef removed identifier, NCT03862144. All participants participated voluntarily and completed a written informed consent.
: Not applicable.
: LC: fees for advisory board (Italfarmaco, Kyowa).MDL: advisory board e SC member (Novartis; Amgen; Eli Lilly; Genentech).VG: institutional research grant (Roche), fees for advisory board (Eli Lilly, Novartis, Roche), speakers bureau (Eli Lilly, Novartis).IP: advisory board (Novartis, Roche, Astrazeneca, Eisai, Italfarmaco, Pfizer, Eli Lilly, Pierre-Fabre), invited speech (Novartis, Roche, Astrazeneca, Pfizer, Eli Lilly).SDP: advisory board (GSK, Novartis, Roche, Celgene, Astrazeneca, Amgen, Eisai, Italfarmaco, Pfizer, Eli Lilly), invited speech (GSK, Novartis, Roche, Celgene, Astrazeneca, Amgen, Pfizer, Eli Lilly).RC: advisory board (Novartis, Italfarmaco).Other authors declare that they have no competing interests.